Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
Open Access
- 10 April 2025
- journal article
- review article
- Published by Springer Nature in Cancer Cell International
- Vol. 25 (1) , 1-11
Abstract
Triple-negative breast cancer (TNBC) is a highly heterogeneous cancer with substantial recurrence potential. Currently, surgery and chemotherapy are the main treatments for this disease. However, chemotherapy is often limited by several factors, including low bioavailability, significant systemic toxicity, inadequate targeting, and multidrug resistance. Immune checkpoint inhibitors (ICIs), including those targeting programmed death protein-1 (PD-1) and its ligand (PD-L1), have been proven effective in the treatment of various tumours. In particular, in the treatment of TNBC with PD-1/PD-L1 inhibitors, both monotherapy and combination chemotherapy, as well as targeted drugs and other therapeutic strategies, have broad therapeutic prospects. In addition, these inhibitors can participate in the tumour immune microenvironment (TIME) through blocking PD-1/PD-L1 binding, which can improve immune efficacy. This article provides an overview of the use of PD-1/PD-L1 inhibitors in the treatment of TNBC and the progress of multiple therapeutic studies. To increase the survival of TNBC patients, relevant biomarkers for predicting the efficacy of PD-1/PD-L1 inhibitor therapy have been explored to identify new strategies for the treatment of TNBC.Keywords
Funding Information
- Jilin Provincial Science and Technology Department Fund (YDZJ202201ZYTS179, YDZJ202301ZYTS131)
- National Natural Science Foundation of China (81960554)
This publication has 69 references indexed in Scilit:
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 studyAnnals of Oncology, 2019
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast CancerNew England Journal of Medicine, 2018
- Immunological differences between primary and metastatic breast cancerAnnals of Oncology, 2018
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenNew England Journal of Medicine, 2018
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trialThe Lancet Oncology, 2018
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse CancersMolecular Cancer Therapeutics, 2017
- Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studyBreast Cancer Research and Treatment, 2017
- Predictive biomarkers for checkpoint inhibitor-based immunotherapyThe Lancet Oncology, 2016
- Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer SubtypesJAMA Oncology, 2016
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 StudyJournal of Clinical Oncology, 2016